| Toxicity |
Interacting Protein |
Mechanism |
Reference |
| 5-Fluorouracil-Associated Toxicity | Dihydropyrimidine dehydrogenase (Q12882) | Severe 5-fluorouracil-associated toxicity (including death) [ ADR Type 2 ] | Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy
|
| Angina Pectoris | Dihydropyrimidine dehydrogenase (Q12882) | It is recommended to measure DPD activity prior to 5-FU based chemotherapy@ which might be helpful in avoiding drug-related toxicity by adjusting the dose of 5-FU individually [ ADR Type 1 ] | Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients
|
| Coma | Dihydropyrimidine dehydrogenase (Q12882) | Cancer patients with DPD deficiency are at increased risk for developing severe neurological toxicity secondary to 5-FU chemotherapy@ and that infusional thymidine should be considered as a potential rescue agent against this particular host toxicity. [ ADR Type 2 ] | Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency
|
| Encephalopathy | Dihydropyrimidine dehydrogenase (Q12882) | Cancer patients with DPD deficiency are at increased risk for developing severe neurological toxicity secondary to 5-FU chemotherapy@ and that infusional thymidine should be considered as a potential rescue agent against this particular host toxicity. [ ADR Type 2 ] | Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency
|
| Gastrointestinal Toxicity | Dihydropyrimidine dehydrogenase (Q12882) | Severe and potentially life-threatening gastrointestinal toxicity@ myelosuppression@ and neurological toxicity [ ADR Type 2 ] | Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency
|
| Hypertension | Dihydropyrimidine dehydrogenase (Q12882) | It is recommended to measure DPD activity prior to 5-FU based chemotherapy@ which might be helpful in avoiding drug-related toxicity by adjusting the dose of 5-FU individually [ ADR Type 1 ] | Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients
|
| Myelosuppression | Dihydropyrimidine dehydrogenase (Q12882) | Severe and potentially life-threatening gastrointestinal toxicity@ myelosuppression@ and neurological toxicity [ ADR Type 2 ] | Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency
|
| Neurological Toxicity | Dihydropyrimidine dehydrogenase (Q12882) | Severe and potentially life-threatening gastrointestinal toxicity@ myelosuppression@ and neurological toxicity [ ADR Type 2 ] | Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency
|